

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

NEURENT MEDICAL INC. & NEURENT MEDICAL LTD.

Petitioners,

v.

AERIN MEDICAL INC.,

Patent Owner.

Case No. IPR2024-00278
U.S. Patent No. 11,033,318

**PETITIONERS' OBJECTIONS TO EVIDENCE
UNDER 37 C.F.R. § 42.64**

Pursuant to 37 C.F.R. § 42.64, Petitioners Neurent Medical Inc. and Neurent Medical Ltd. (collectively, “Neurent” or “Petitioners”) submit the following objections to evidence served with Patent Owner’s Response on October 25, 2024. Petitioners’ objections apply equally to Patent Owner’s reliance on these exhibits in any subsequently-filed documents. These objections are timely, having been filed within five business days of Patent Owner serving the evidence. *See* 37 C.F.R. § 42.64.

A. Exhibit 2001

Petitioners object to Exhibit 2001 under Federal Rule of Evidence (“FRE”) because the opinions contained therein are conclusory and lack sufficient explanation. The opinions are not based on sufficient facts or data and are not the product of reliable principles and methods reliably applied to the facts of the case. *See* 37 C.F.R. § 42.65. To the extent that Exhibit 2001 purports to provide legal conclusions, Petitioners object under FRE 702.

B. Exhibit 2003

Petitioners preserve and restate their objections to specific portions of Dr. Martin’s cross-examination testimony taken during the deposition on September 24, 2024. To the extent Patent Owner has relied or will rely on portions of the testimony that were objected to during the deposition, Petitioners maintain those objections

and the grounds for such objections. Petitioners also reserve the right to serve an errata for Dr. Martin's deposition transcript, and object to portions of the transcript on which Patent Owner relies that are subject to the errata.

C. Exhibit 2004

Petitioners preserve and restate their objections to specific portions of Dr. Martin's cross-examination testimony taken during the deposition on September 25, 2024. To the extent Patent Owner has relied or will rely on portions of the testimony that were objected to during the deposition, Petitioners maintain those objections and the grounds for such objections. Petitioners also reserve the right to serve an errata for Dr. Martin's deposition transcript, and object to portions of the transcript on which Patent Owner relies that are subject to the errata.

D. Exhibit 2005

Petitioners preserve and restate their objections to specific portions of Dr. Martin's cross-examination testimony taken during the creation of Exhibit 6 to Dr. Martin's deposition on September 25, 2024. To the extent Patent Owner has relied or will rely on portions of the testimony that were objected to during the deposition, Petitioners maintain those objections and the grounds for such objections. Petitioners also reserve the right to serve an errata for Dr. Martin's deposition

transcript, and object to portions of the transcript on which Patent Owner relies that are subject to the errata.

Petitioners further object to Exhibit 2005 under FRE 401, 402, and 403 as lacking relevance and because its probative value is substantially outweighed by the danger of unfair prejudice, confusing the issues, misleading the fact finder, undue delay, wasting time, and/or needlessly presenting cumulative evidence.

Petitioners further object to Exhibit 2005 under FRE 106 as being an incomplete document, and under FRE 602 as not based on a reliable foundation.

E. Exhibit 2006

Petitioners preserve and restate their objections to specific portions of Dr. Martin's cross-examination testimony taken during the creation of Exhibit 7 to Dr. Martin's deposition on September 25, 2024. To the extent Patent Owner has relied or will rely on portions of the testimony that were objected to during the deposition, Petitioners maintain those objections and the grounds for such objections. Petitioners also reserve the right to serve an errata for Dr. Martin's deposition transcript, and object to portions of the transcript on which Patent Owner relies that are subject to the errata.

Petitioners further object to Exhibit 2006 under FRE 401, 402, and 403 as lacking relevance and because its probative value is substantially outweighed by the

danger of unfair prejudice, confusing the issues, misleading the fact finder, undue delay, wasting time, and/or needlessly presenting cumulative evidence.

Petitioners further object to Exhibit 2006 under FRE 106 as being an incomplete document, and under FRE 602 as not based on a reliable foundation.

F. Exhibit 2007

Petitioners preserve and restate their objections to specific portions of Dr. Martin's cross-examination testimony taken during the creation of Exhibit 8 to Dr. Martin's deposition on September 25, 2024. To the extent Patent Owner has relied or will rely on portions of the testimony that were objected to during the deposition, Petitioners maintain those objections and the grounds for such objections. Petitioners also reserve the right to serve an errata for Dr. Martin's deposition transcript, and object to portions of the transcript on which Patent Owner relies that are subject to the errata.

Petitioners further object to Exhibit 2007 under FRE 401, 402, and 403 as lacking relevance and because its probative value is substantially outweighed by the danger of unfair prejudice, confusing the issues, misleading the fact finder, undue delay, wasting time, and/or needlessly presenting cumulative evidence.

Petitioners further object to Exhibit 2007 under FRE 106 as being an incomplete document, and under FRE 602 as not based on a reliable foundation.

Respectfully submitted,

By: /David L. Cavanaugh/
David L. Cavanaugh
Registration No. 36,476

Counsel for Petitioners

CERTIFICATE OF SERVICE

I hereby certify that, on November 1, 2024, I caused a true and correct copy of the following materials:

- Petitioners' Objections to Evidence Under 37 C.F.R. § 42.64

to be served on Patent Owner via electronic mail to:

Heath J. Briggs, BriggsH@gtlaw.com;

Trenton Ward, Trenton.Ward@gtlaw.com;

Benjamin P. Gilford, gilfordb@gtlaw.com;

Elana Araj, Elana.Araj@gtlaw.com;

Stephen M. Ullmer, UllmerS@gtlaw.com; and

AerinMed-IPRs@gtlaw.com.

/Brian J. Lambson/

Brian J. Lambson

Registration No. 72,570